Brief: Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models
18/09/2017 12:03
Sept 18 (Reuters) - Bellus Health Inc BLU.TO
* Bellus Health's BLU-5937 significantly reduces cough
without taste disturbance in two preclinical models
* Bellus Health Inc - BLU-5937's reduction in cough
frequency comparable to leading P2X3 antagonist, Gefapixant
* Bellus - in rat taste model, BLU-5937 didnt inhibit taste;
but consistent with trial data presented by Merck, Gefapixant
did significantly impact taste
Source text for Eikon: ID:nCNWbdq0Ha
Further company coverage: BLU.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on BELLUS Health
See all newsBrief: Bellus Health Inc. Calls Special Shareholders’ Meeting In Connection With Gsk Acquisition
Brief: Bellus Health Reports First Quarter 2023 Financial Results And Business Highlights
Press Digest: British Business - April 19
Canada Stocks: Toronto market extends winning streak on 'soft landing' hopes
Bellus soars as GSK plans to buy drug developer for $2 bln